Development of Broad Coronavirus Immunity Targeting the Fusion Peptide

Document text

Principal Investigator: Daniel  Kulp
Organization: WISTAR INSTITUTE
Fiscal Year: 2022
Award: $228,788
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary
This revised application was originally responding to the Emergency Award ‘Rapid Investigation of Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)’
submitted through PAR-20-177. However, we are submitting the revised application, upon advice from NIH, to
the parent PA-20-195 with a due date of Nov 16th 2020. The application is titled ‘Development of Broad
Coronavirus Immunity Targeting the Fusion Peptide’. The assembled team brings together highly
complementary expertise in order to develop a unique coronavirus vaccine approach to provide more effective,
focused and broadened humoral immunity. This proposal focuses on the fusion peptide site of
vulnerability as it has been understudied, it is highly conserved and recently been identified as an
epitope of neutralizing antibodies in human convalescent sera. The project aims are: (1) Develop pan-
coronavirus fusion peptide nanoparticle and trimer immunogens (2) Develop immunization regimes to induce
broadly neutralizing antibodies using nucleic acid delivery.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Advanced Development><Algorithm Design><Algorithmic Design><Algorithmic Engineering><Animals><Antibodies><Antigenic Determinants><Antigens><Award><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><Biophysics><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Cell Mediated Immunology><Cell-Mediated Immunity><Cellular Immunity><China><Cities><Clinical><CoV S protein><CoV emergence><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><CoV-2><CoV2><Communicable Diseases><Coronaviridae><Coronavirus><Coronavirus glycoprotein S><Coronavirus spike protein><DNA delivery><Denmark><Development><Devices><Disease><Disease Outbreaks><Disorder><Drugs><Electroporation><Emergencies><Emergency Situation><Epitopes><Evaluation><Extensive Disease><Frequencies><GS-5734><Generalized Disease><Generations><Genetic><Genetic Alteration><Genetic Change><Genetic defect><Glycans><HCoV><Human><Humoral Immunities><Immune><Immune response><Immunes><Immunity><Immunization><Immunization Programs><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Investigation><Length><Link><MERS><MERS corona virus><MERS coronavirus><MERS coronavirus disease><MERS virus><MERS-CoV><MERS-CoV disease><Mainland China><Medication><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome coronavirus disease><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome-CoV><Mink><Modern Man><Molecular Interaction><Mutate><Mutation><NIH><National Institutes of Health><Outbreaks><Parents><Peptides><Pharmaceutic Preparations><Pharmaceutical Preparations><Plasmids><Polymerase><Polysaccharides><Population><Proteins><Publishing><Reagent><Recovery><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Site><Structure><Technology><Therapeutic><Time><Translations><Transmission><United States National Institutes of Health><Vaccination Programs><Vaccine Clinical Trial><Vaccines><Veklury><Virus><Widespread Disease><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><algorithm engineering><algorithmic composition><animal data><antibody-based immunity><base><biophysical foundation><biophysical principles><biophysical sciences><combat><convalescent plasma><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus S protein><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><coronavirus spike glycoprotein><coronavirus vaccine><cross reactivity><deliver DNA><design><designing><developmental><drug/agent><electroporative delivery><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experiment><experimental research><experimental study><gene electrotransfer><genome mutation><hCoV19><host response><human CoV><human corona virus><human coronavirus><immune system response><immunogen><immunogenic><immunoresponse><improved><inhibitor><interest><medical countermeasure><nCoV><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><nucleic acid delivery><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><plasmid DNA><pre-clinical><preclinical><remdesivir><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome-CoV><small molecule><transmission process><vaccine against coronavirus><vaccine effectiveness>